TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published in JAMA Network Open compared dementia rates among more than 830,000 adults newly treated for overactive bladder and found similar rates for anticholinergic drugs and beta-3 agonists. The observational study does not prove either class is risk-free or show that overactive bladder is an early sign of dementia.
A study of 830,393 adults newly treated for overactive bladder found similar dementia rates among patients prescribed anticholinergic medications and those prescribed beta-3 agonists, challenging the assumption that the newer drug class carries less long-term dementia risk. The findings, published November 6 in JAMA Network Open, do not establish that either type of medication is risk-free.
Researchers at the University Hospitals Cleveland Medical Center Urology Institute used Epic Cosmos, a national electronic health record database, to examine adults aged 40 to 90 who began overactive bladder treatment between 2012 and 2025. They compared dementia incidence among people taking anticholinergics, a long-established treatment, and people taking beta-3 agonists, a newer class often considered a safer option for the brain.
The report says dementia rates were similar across the two drug classes and individual medications. The study compared treated patients with one another; it did not include a group of people with overactive bladder who took no medication. Its results therefore do not answer whether either class changes dementia risk compared with no drug treatment.
Lead author David Sheyn, a urogynecologist at the institute, said the results are new and should be reproduced before clinical guidance changes. The report also notes that beta-3 agonists remain the preferred choice when possible, while anticholinergic drugs can cause short-term cognitive and memory side effects for some users.
How the Findings Could Affect OAB Treatment
Concerns about a possible link between anticholinergic medicines and dementia can make people reluctant to use drugs that may ease overactive bladder symptoms. The similar rates reported in this study may inform those discussions, but they do not establish that anticholinergics are harmless over the long term or that patients should change treatment. The findings are a comparison between two treated groups, not a test of medication against no treatment.
The research also raises a separate possibility: overactive bladder, or the neurological changes associated with it, might sometimes precede dementia. That idea could matter for earlier recognition of neurological disease, but this study does not prove that OAB is an early warning sign. Patients should discuss medication choices and cognitive symptoms with a qualified health professional, rather than making changes based on one observational study.
Products Worth Considering
Withings Sleep Under-Mattress Sleep Tracking Pad
BowFlex Results Series SelectTech Adjustable Dumbbells (Pair)
Hyperice Hypervolt 3 Percussion Massage Gun with Heated Head and Carry Case
As an affiliate, we earn on qualifying purchases.
Why Researchers Compared These Drugs
Anticholinergic medicines have long been used as a second-line medication treatment for overactive bladder. Earlier observational studies linked their use to dementia, prompting concern among clinicians and patients. Beta-3 agonists are a newer alternative that has been presumed to pose less risk to the brain.
Sheyn said one reason for undertaking the research was that the biological process leading to dementia may begin decades before symptoms appear, while many earlier studies of bladder medicines followed patients for five years or less. The new analysis used a much larger patient group and a longer period of available records, but it remains an observational comparison. The report is based on the study by Sheyn and colleagues, “Drug therapies and incidence of dementia among adults with overactive bladder,” published in JAMA Network Open (DOI: 10.1001/jamanetworkopen.2026.42026).
““These results are still new and will require reproduction prior to a change in clinical guidelines.””
— David Sheyn, lead author and urogynecologist at University Hospitals Cleveland Medical Center Urology Institute
Limits of the Dementia Comparison
The findings do not establish whether either medication class increases dementia risk compared with taking no medication, because the study had no untreated comparison group. As an observational analysis of health records, it also cannot by itself determine that a drug caused or prevented dementia, or exclude other differences between patients in the two treatment groups.
The study does not prove that overactive bladder is an early sign of dementia. The report says the pattern is consistent with that possibility, but further research is needed to test it. The available source does not provide detailed effect estimates, follow-up duration for each patient, or a precise measure of how similar the dementia rates were. Short-term cognitive and memory side effects associated with anticholinergics also remain a concern, according to Sheyn.
Replication Before Guidance Changes
Researchers will need to see the findings reproduced in other studies before they can support a change in clinical guidelines. Further research could also examine whether OAB itself, the neurological processes behind it, or other factors account for any relationship with later dementia. Until then, the study offers a new comparison between two medication classes, not a general safety guarantee. People weighing treatment options should consult their clinician about benefits, side effects and personal health circumstances.
Key Questions
What did the study find about overactive bladder drugs and dementia?
It found similar dementia rates among adults treated with anticholinergic medications and beta-3 agonists. It did not compare either group with people who took no medication.
Does this prove anticholinergic drugs do not cause dementia?
No. The study was observational and compared two treated groups. It cannot prove that anticholinergics cause no harm or rule out a risk compared with no treatment.
Should patients switch or stop their medication?
The findings alone are not a reason to stop or change a prescription. Patients should discuss treatment choices, side effects and concerns with a qualified health professional.
Does overactive bladder mean someone may develop dementia?
No such conclusion can be drawn from this study. The researchers said the results fit a possible link between OAB and early neurological changes, but do not prove that OAB is a dementia warning sign.
Source: news-medical.net
